FDA approves Cerus system to cut blood transfusion infections

(Reuters) - U.S. health regulators on Tuesday approved a device developed by Cerus Corp to reduce the risk of infections in blood plasma transmitted during transfusions, such as HIV, hepatitis and West Nile virus, sending company shares 25 percent higher. The Intercept Blood System for plasma uses ultraviolet light and a chemical called amotosalen that inactivates viral pathogens in the blood. The plasma is then purified to remove the chemical and its byproducts. ...



via Health News Headlines - Yahoo News http://ift.tt/1IZ45uG